高级检索
当前位置: 首页 > 详情页

A Response Surface Analysis of the Combination of Dexmedetomidine and Sufentanil for Attenuating the Haemodynamic Response to Endotracheal Intubation

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Anesthesiol, 1095 Jie Fang Rd, Wuhan 430030, Peoples R China [2]Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Anesthesiol, Chengdu, Peoples R China
出处:
ISSN:

关键词: dexmedetomidine sufentanil response surface endotracheal intubation

摘要:
Purpose: Dexmedetomidine combined with opioids has been extensively used to blunt cardiovascular responses to endotracheal intubation. To determine their interaction, we aimed to develop a response surface model between dexmedetomidine and sufentanil. Methods: One hundred and twenty patients undergoing scheduled gynaecological surgery were recruited. According to a simulation of slice design, patients received different dose pairs of dexmedetomidine (0 to 1.1 mu g/kg) and sufentanil (.1 to .5 mu g/kg). The mean arterial blood pressure and heart rate of patients were recorded just before endotracheal intubation, immediately after intubation, and during the first 3 min after intubation. The primary outcomes were haemodynamic changes. The full dose-response relationship between dexmedetomidine and sufentanil was analysed using a logit model. Results: This response surface model revealed that the interaction between dexmedetomidine and sufentanil was additive. The dose pairs that could effectively attenuate the haemodynamic response to endotracheal intubation primarily ranged from .3 to .4 mu g/kg and .5 to 1.1 mu g/kg for sufentanil and dexmedetomidine, respectively. Conclusion: When used propofol as the main hypnotic drug during anaesthesia induction, dexmedetomidine could effectively reduce the requirement of sufentanil in an additive manner. However, it is not an effective drug for ablating the cardiovascular response to endotracheal intubation when used alone.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 药学 4 区 核医学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 药学 4 区 核医学
JCR分区:
出版当年[2020]版:
Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Anesthesiol, 1095 Jie Fang Rd, Wuhan 430030, Peoples R China [2]Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Anesthesiol, Chengdu, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:432 今日访问量:0 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)